title: Sample size requirements for studies of treatment effects on beta-cell function in newly diagnosed type 1 diabetes.
abstract: Preservation of β-cell function as measured by stimulated C-peptide has recently been accepted as a therapeutic target for subjects with newly diagnosed type 1 diabetes. In recently completed studies conducted by the Type 1 Diabetes Trial Network (TrialNet), repeated 2-hour Mixed Meal Tolerance Tests (MMTT) were obtained for up to 24 months from 156 subjects with up to 3 months duration of type 1 diabetes at the time of study enrollment. These data provide the information needed to more accurately determine the sample size needed for future studies of the effects of new agents on the 2-hour area under the curve (AUC) of the C-peptide values. The natural log(x), log(x+1) and square-root (√x) transformations of the AUC were assessed. In general, a transformation of the data is needed to better satisfy the normality assumptions for commonly used statistical tests. Statistical analysis of the raw and transformed data are provided to estimate the mean levels over time and the residual variation in untreated subjects that allow sample size calculations for future studies at either 12 or 24 months of follow-up and among children 8-12 years of age, adolescents (13-17 years) and adults (18+ years). The sample size needed to detect a given relative (percentage) difference with treatment versus control is greater at 24 months than at 12 months of follow-up, and differs among age categories. Owing to greater residual variation among those 13-17 years of age, a larger sample size is required for this age group. Methods are also described for assessment of sample size for mixtures of subjects among the age categories. Statistical expressions are presented for the presentation of analyses of log(x+1) and √x transformed values in terms of the original units of measurement (pmol/ml). Analyses using different transformations are described for the TrialNet study of masked anti-CD20 (rituximab) versus masked placebo. These results provide the information needed to accurately evaluate the sample size for studies of new agents to preserve C-peptide levels in newly diagnosed type 1 diabetes.
authors.affiliation: The Biostatistics Center, The George Washington University, Rockville, Maryland, United States of America. jml@bsc.gwu.edu
authors.forename: John M
authors.initials: JM
authors.lastname: Lachin
authors.forename: Paula L
authors.initials: PL
authors.lastname: McGee
authors.forename: Carla J
authors.initials: CJ
authors.lastname: Greenbaum
authors.forename: Jerry
authors.initials: J
authors.lastname: Palmer
authors.forename: Mark D
authors.initials: MD
authors.lastname: Pescovitz
authors.forename: Peter
authors.initials: P
authors.lastname: Gottlieb
authors.forename: Jay
authors.initials: J
authors.lastname: Skyler
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D019540:Area Under Curve; D002096:C-Peptide / Q000378:metabolism; D002648:Child; D015331:Cohort Studies; D000077561:Daclizumab; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D050417:Insulin-Secreting Cells / Q000187:drug effects* / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000069283:Rituximab; D018401:Sample Size; D055815:Young Adult
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D002096:C-Peptide; D007074:Immunoglobulin G; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D000069283:Rituximab; D000077561:Daclizumab; D009173:Mycophenolic Acid
references.citation: Biometrics. 1947 Mar;3(1):39-52
references.pmid: 20240416
references.citation: Diabetes Care. 2010 Apr;33(4):826-32
references.pmid: 20067954
references.citation: N Engl J Med. 2008 Oct 30;359(18):1909-20
references.pmid: 18843118
references.citation: Diabetes Care. 2008 Oct;31(10):1966-71
references.pmid: 18628574
references.citation: N Engl J Med. 2009 Nov 26;361(22):2143-52
references.pmid: 19940299
references.citation: N Engl J Med. 1994 Nov 24;331(21):1428-36
references.pmid: 7969282
references.citation: Control Clin Trials. 1999 Dec;20(6):547-54
references.pmid: 10588295
references.citation: Control Clin Trials. 1981 Jun;2(2):93-113
references.pmid: 7273794
references.citation: Diabetes. 2004 Jan;53(1):250-64
references.pmid: 14693724
references.citation: N Engl J Med. 2002 May 30;346(22):1692-8
references.pmid: 12037148
references.citation: N Engl J Med. 2005 Jun 23;352(25):2598-608
references.pmid: 15972866
references.citation: J Diabetes Sci Technol. 2009 Mar 01;3(2):320-30
references.pmid: 20144363
references.citation: Lancet. 2001 Nov 24;358(9295):1749-53
references.pmid: 11734230